#TWIST BIOSCIENCE SOFTWARE#

Twist is also nowhere near profitability, with a cash burn that exceeds its entire revenue base. The company is investing in a facility to double capacity, so given the expanding use cases for the technology, I expect growth to remain quite strong for the upcoming five year period (would revisit in the future to determine longer-term period). Analysts are currently estimating $120 million for FY21 (33% YoY growth), and $166 million in FY22 (38% YoY growth). Twist has exhibited torrid revenue growth, and that is projected to continue.

That being one with a rapidly expanding revenue base, that is operating at a loss because every dollar the company brings in is pumped back into the company to continue expansion efforts. Looking At The FinancialsĪs a young company founded in 2013 (and went public in 2018), it's reasonable to expect the financial profile of a typical growth company. The semiconductor was transformative for electronics, and I think that a similar leap can be realized in biotechnology. Think of Twist inventing the 'semiconductor' of DNA synthesis.

#TWIST BIOSCIENCE SOFTWARE#

It is almost a certainty that as technology advances within DNA synthesis, that more applications and uses will emerge - increasing the total addressable market for companies such as Twist Bioscience.ĭNA synthesis is a busy field (as is much of the biotech sector), but Twist brings a unique 'twist' with their technology that utilizes software and silicon to bring much larger and more efficient scale to DNA synthesis than traditional methods. DNA synthesis is driving innovation in many industries such as chemicals, food and agriculture, healthcare, energy and biofuels, and more. DNA synthesis is not a ground-breaking concept, but the technology and science behind the concept has matured a bit in recent years. Twist is a company that uses proprietary technology to commercially produce synthetic DNA. While there are risks to an investor in Twist, the long-term potential is notable despite a steep valuation. Biotechnology company Twist Bioscience ( NASDAQ: TWST ) is in early stages of combining technology and biology in a manner that offers the potential to completely reinvent entire industries. Along with that, is continued progress towards major breakthroughs in how we manipulate nature's most complex creation - genomics. We are steadily seeing sweeping advancements in healthcare, and how we treat disease.

Today, innovation moves at a pace that is potentially faster than any point in history. “I think the biggest innovations of the 21st century will be the intersection of biology and technology. Since 2019, Andreas has been Head of Quality Management and Regulatory Affairs at Platomics.Photo by Tetiana Lazunova/iStock via Getty Images Furthermore, he is a member of the Austrian Standards Committee 179 for Medical Technology. Building on this background, Andreas successfully managed and conducted relevant development and consulting projects for more than 15 years and shared his knowledge in a longstanding role as external lecturer for Regulatory Affairs at UAT Technikum Vienna. As Senior Research Engineer at AIT, Austria’s largest non-university research institution, Andreas was responsible for the implementation and maintenance of the company’s certified quality management system (ISO 13485), as well as the regulatory compliance of AIT’s medical devices. As a developer, safety engineer, and project manager for medical device development projects, he gained experience in the technical realization of relevant diagnostic and therapeutic products, specifically in non-invasive cardiovascular diagnostics and neurorehabilitation. Andreas holds a degree in Biomedical Engineering and has worked in the field of Medical Device Regulation since 2002.

Twist bioscience